As part of the grant, AvidBiotics will receive $600,000 funds spreading over two years.
AvidBiotics chief executive officer David Martin said Clostridium difficile has become the most frequent cause of hospital-acquired infections overtaking methicillin-resistant Staph. Aureus.
"This new funding will help support our preclinical research and advance Avidocin™ proteins towards the clinic," Martin added.
AvidBiotics’ Avidocin antibacterial proteins will kill target organisms without collateral damage to non-targeted bacteria in bacterial health threats.